Evaluating the Primary Prevention of Ischemic Stroke of Oral Antithrombotic Therapy in Head and Neck Cancer Patients with Radiation Therapy

Table 3

Association of study outcomes in head and neck cancer patients with radiation therapy between oral antithrombotic therapy users and nonusers.

Follow-up method	Outcome	Crude HR	95% CI		value	Adjusted HR^†	95% CI		value
			Lower	Upper			Lower	Upper
Study population
Method I	Ischemic stroke or TIA	1.923	1.244	2.972	0.0032	1.214	0.776	1.898	0.3961
	Death	1.493	1.085	2.053	0.0138	1.306	0.945	1.806	0.1062
	Major bleeding	1.237	0.914	1.675	0.1678	0.951	0.699	1.294	0.7490
Method II	Ischemic stroke or TIA	1.395	0.345	5.646	0.6403	0.812	0.199	3.309	0.7712
	Death	1.915	1.228	2.988	0.0042	1.662	1.059	2.607	0.0271
	Major bleeding	1.391	0.819	2.363	0.2215	1.057	0.620	1.802	0.8397
Study population after 1-to-1 propensity score matching
Method I	Ischemic stroke or TIA	1.727	0.849	3.512	0.1313	1.609	0.779	3.325	0.1988
	Death	1.442	0.878	2.369	0.1484	1.511	0.916	2.493	0.1061
	Major bleeding	0.888	0.586	1.346	0.5758	0.875	0.575	1.330	0.5313
Method II	Ischemic stroke or TIA	0.666	0.142	3.130	0.6068	0.506	0.110	2.330	0.3816
	Death	1.458	0.833	2.550	0.1865	1.450	0.822	2.556	0.1995
	Major bleeding	0.951	0.512	1.768	0.8748	0.853	0.460	1.583	0.6149

HR, hazard ratio; CI, confidence interval; TIA, transient ischemic attack.
variables included age, gender, comorbidity, and prescribed drugs.